Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration

Key Points

• The study aims to evaluate the efficacy of switching from aflibercept to ranibizumab in treating neovascular age-related macular degeneration.
• Compared visual outcomes after switching treatments
• Analyzed the impact of age and previous injections
• Measured changes in central macular thickness (CMT)
• Switching to ranibizumab resulted in non-inferior visual outcomes
• Age and previous injections influenced CMT changes
• Findings support the potential for optimizing treatment strategies through drug switching

Abstract